Valued at more than $9 billion, Theranos says it has developed a revolutionary approach to blood testing. It has raised millions of dollars on its claim that its technology can "quickly process the full range of laboratory tests from a few drops of blood."
The FDA's reports call the company's proprietary vial -- or "nanotainer" -- an "uncleared medical device." This tiny vial is designed to collect small amounts of blood from finger pricks.